Bio-Technopark

In very close proximity to the Swiss Federal Institute of Technology (ETH), the University and Zurich University Hospital, a science park for life science companies and institutions has developed in the last two decades, which has now acquired both national and international significance. On an area of 55,000 m2, the park now hosts more than 40 companies and many academic institutions representing a healthy mix of young start-ups and global companies as well as university clinics, institutes, and research groups.

read more

Leasing

In the Bio-Technopark, it is possible to rent ultramodern laboratories, offices, and complex infrastructure for research and development purposes. The premises offered include fully-equipped laboratory facilities with communal infrastructure, and individual rental areas in different sizes and locations and with different fit-out standards. The Bio-Technopark is still being developed and gradually fitted out.

read more

Services

The Bio-Technopark promotes the transfer of knowledge and technology, as well as the foundation and building up of life science companies. In addition to advice, coaching, and support for those who are setting up and developing companies and looking for financing, its services include the organization of events that focus on networking, facilitating the exchange of ideas between specialists, and advanced training.

 

read more

News

Kuros Biosciences Expands License Agreement with Checkmate

Kuros announced that it has amended its exclusive license agreement, which was originally signed in 2015, that grants Checkmate Pharmaceuticals Inc., Cambridge, MA, USA (“Checkmate”) access to Kuros’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis. The amendment extends the field...

read more

Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma

Molecular Partners AG announced initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma (MM). Eight patients have been treated in the first cohort of 8 mg/kg MP0250 and were included in the safety analysis set. No dose-limiting toxicities (DLTs) have been reported to date....

read more

Events

  • Life Science Zurich Impact: Conference on Translational Medicine
    22.01.2018
  • Specialist Seminar
    23.01.2018
  • Bio-Technopark After Work Networking Aperitif
    06.02.2018